Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to Staphylococcus

Trial Profile

Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to Staphylococcus

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afabicin (Primary) ; Afabicin (Primary) ; Cefazolin; Clindamycin; Clindamycin; Linezolid; Linezolid; Vancomycin
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Adverse reactions
  • Sponsors Debiopharm
  • Most Recent Events

    • 01 Oct 2019 Status changed from recruiting to active, no longer recruiting.
    • 27 May 2019 Planned End Date changed from 1 Nov 2019 to 23 Jul 2020.
    • 27 May 2019 Planned primary completion date changed from 1 Nov 2019 to 23 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top